Skip to main content

Prostate cancer

14-09-2018 | Prostate cancer | Highlight | Article

Editor's pick

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.


BMJ 2018; 362: k3519, k3702

13-09-2018 | Prostate cancer | News | Article

HRQoL unaffected by addition of apalutamide to androgen deprivation therapy

The addition of apalutamide to androgen deprivation therapy has no detrimental effect on health-related quality of life in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.


Lancet Oncology 2018; doi:10.1016/S1470-2045(18)30456-X

04-09-2018 | Prostate cancer | News | Article

Steroid SWITCHing may benefit mCRPC patients who progress on abiraterone

A phase II proof-of-concept study has shown that clinically stable patients with metastatic castration-resistant prostate cancer and limited disease progression during treatment with abiraterone acetate plus prednisone can experience biochemical and radiologic responses following a steroid switch to dexamethasone.


Br J Cancer 2018; doi:10.1038/s41416-018-0123-9

31-08-2018 | Prostate cancer | News | Article

Moderately hypofractionated radiotherapy regimen promising for localized prostate cancer

Intensity-modulated radiation therapy using a moderately hypofractionated, dose-escalated regimen may control localized prostate cancer better than a conventional regimen while shortening treatment duration, a phase III trial suggests.


J Clin Oncol 2018; doi:10.1200/JCO.2018.77.9868

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.


Ann Oncol 2018; doi:10.1093/annonc/mdy263

27-07-2018 | Prostate cancer | News | Article

Editor's pick

Robot-assisted laparoscopy meets open radical prostatectomy for functional outcomes

Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.


Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30357-7
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30417-0

image credits